A family member has rectal cancer that has spread to their lungs and liver. It has been suggested to add Erbitux to their Folfox treatments.
Their diagnostic finding showed that they were NRAS Wildtype but their KRAS was Amplification.
Is there benefit to add Erbitux with this genetic makeup?
Thanks!